Clinical Trial: Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07596784) titled 'Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)' on May 13.

Brief Summary: The primary purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in Chinese adult participants with Acetylcholine receptor (AChR) + Generalized Myasthenia Gravis (gMG).

Study Start Date: July 30

Study Type: INTERVENTIONAL

Condition: Generalized Myasthenia Gravis gMG

Intervention: DRUG: Ravulizumab

Participants will receive ravulizumab via intravenous (IV) infusion.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Alexio...